Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 14/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975622 | 1.00 | GPR119 (0.41) | GPR119TRPA1SLC22A12EGLN2KDM1A | |
| SCHEMBL20512862 | 0.86 | CYP11B2 (0.41) | SLC22A12KDM1ACYP11B1CYP11B2 | |
| SCHEMBL20512647 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20512514 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20512516 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL23496011 | 0.80 | KDM1A (0.48) | GPR119KDM1A | |
| SCHEMBL20512481 | 0.80 | KDM1A (0.48) | GPR119KDM1A | |
| SCHEMBL20512598 | 0.79 | TRPA1 (0.47) | GPR119TRPA1SLC22A12EGLN2KDM1A | |
| SCHEMBL17981584 | 0.79 | BACE1 (0.40) | — | |
| SCHEMBL29927427 | 0.78 | KDM1A (0.48) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023076302-A1 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | ASTEX PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-11479563-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
| CN-108602770-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2022-02-08 | — | — | CN | disclosed |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10723742-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-3632897-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632443-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-3633380-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-110740991-A | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2020-01-31 | — | — | CN | disclosed |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3381896-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | KDM1B, KDM1A, DOT1L | GPR119 577/4885TRPA1 3202/4885SLC22A12 3218/4885 |
| US-10723742-B2 | Biphenyl compound or salt thereof | KDM1B, BMI1, HDAC1 | GPR119 1352/4885TRPA1 1788/4885SLC22A12 2361/4885 |
| US-11479563-B2 | Biphenyl compound or salt thereof | BMI1, KDM1B, KDM1A | GPR119 1186/4885TRPA1 1366/4885SLC22A12 2119/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | GPR119 460/4885TRPA1 4871/4885SLC22A12 3441/4885 |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | INMT, CARM1, KDM1B | GPR119 460/4885TRPA1 4871/4885SLC22A12 3441/4885 |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, HDAC1, DOT1L | GPR119 796/4885TRPA1 1973/4885SLC22A12 1982/4885 |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | KDM1B, KDM1A, DOT1L | GPR119 577/4885TRPA1 3202/4885SLC22A12 3218/4885 |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, KDM1A, HDAC1 | GPR119 712/4885TRPA1 1661/4885SLC22A12 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.